Pediatricians prefer Merck, GSK and Sanofi, says SDI study

Share this article:
Sanofi-Aventis jumped from sixth place to third in terms of its reputation among pediatricians, trailing only Merck and GlaxoSmithKline in the top spots, according to an SDI study.

When asked how Sanofi had garnered their favor this year, nearly 40% of the physicians surveyed credited the company's vaccines or immunization support programs. Sanofi ramped up detailing efforts by 45% this year, particularly in support of its Pentacel vaccine, an immunization for diphtheria, tetanus and other diseases, and Xyzal, the company's near-blockbuster allergy treatment.

In the US, Sanofi's sponsored meetings and events for pediatricians increased by almost 72% since last year, with almost half of the events promoting Pentacel or Xyzal.

“It's noteworthy that pediatricians' opinions of Sanofi-Aventis US were elevated so much in the course of one year, said Healther Alba, SDI senior product manager, in a statement.

SDI's pharma company image study surveyed close to 10,000 participants, including physicians nurse practitioners, physician assistants and others.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...